Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 3

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Fallopian Tube Neoplasms 10Ovarian Neoplasms 7Endometrial Neoplasms 5Breast Neoplasms 4Prostatic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Osteosarcoma 2Neuroendocrine Tumors 2Neuroblastoma 2Neoplasms 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Glioma 2Glioblastoma 2Ependymoma 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1

Interventions

enzalutamide 21Magnetic Resonance Spectroscopy 21apalutamide 17Androgen Antagonists 14Specimen Handling 13Prednisone 13Abiraterone Acetate 13abiraterone 9Docetaxel 9Radiotherapy 8Biopsy 8darolutamide 7Radiosurgery 7Pluvicto 7Nivolumab 7cabazitaxel 6Lutetium-177 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6Lutetium 5radium Ra 223 dichloride 4pembrolizumab 4niraparib 4gallium 68 PSMA-11 4cabozantinib 4bicalutamide 4atezolizumab 4Watchful Waiting 4Surveys and Questionnaires 4Standard of Care 4Radiotherapy, Intensity-Modulated 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Neoplasms × olaparib × 30 days × Clear all
NCT03012321 2026-06-01

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Northwestern University

Phase 2 Active not recruiting
70 enrolled
Genitourinary

Prostatic Neoplasms

NCT02893917 2026-05-28

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
90 enrolled 19 charts
Genitourinary

Prostatic Neoplasms

NCT03317392 2026-05-20

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
132 enrolled 22 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡